SUBSCRIBE
SUBSCRIBE

AbbVie

AbbVie’s mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women’s health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter, Facebook, Instagram, and YouTube.

We are AbbVie. A global Fortune 500 biopharmaceutical company creating life-changing medicines and first-in-kind solutions that make a real difference in people’s lives.

Our 50,000+ employees across geographies, disciplines, and therapeutic areas put impact at the core of every decision. With over $50B invested in R&D since our founding in 2013, we’re always focused on helping people and communities thrive for generations to come.

  • 2025 BPTW Badge - RBG.png
  • 2024 Best Places to Work
  • 2023 Best Places to Work
  • 2022 Best Places to Work
1 North Waukegan Road
North Chicago, IL 60064
Tel: 1-800-255-5162
Visit website
Email Us
Stock Symbol: ABBV
Stock Exchange: NYSE
  • Featured Employer
NEWS
AbbVie_© AbbVie Inc. All rights reserved.
Drug Development
AbbVie, J&J Pull Two Accelerated Approvals for Imbruvica
AbbVie and Johnson & Johnson will withdraw the accelerated approvals for Imbruvica in mantle cell lymphoma and marginal zone lymphoma, the companies announced Thursday.
April 10, 2023
 · 
2 min read
 · 
Tristan Manalac
Sarah Silbiger/Getty Images
FDA
FDA Action Alert: Alvotech, Otsuka and More
The FDA is set to decide on a Humira biosimilar and hold an Adcomm meeting for an Alzheimer’s agitation treatment. Also on its calendar for April are decision dates for two vaccine hopefuls.
April 7, 2023
 · 
4 min read
 · 
Tristan Manalac
SKYRIZI is the new option for psoriatic arthritis.
Drug Development
AbbVie Clinches Back-to-Back Clinical Wins in Ulcerative Colitis, Lupus
In a double data drop Thursday, AbbVie touted two clinical trial wins, for Skyrizi in ulcerative colitis and Rinvoq in systemic lupus erythematosus.
March 24, 2023
 · 
2 min read
 · 
Tristan Manalac
Business
Raises for Moderna, Pfizer CEOs Highlight Continuing Trend
As demand for biotech talent increases, the need to offer competitive pay to the average employee puts financial pressure on companies to increase CEO pay as well.
March 20, 2023
 · 
2 min read
 · 
Jia Jie Chen
SKYRIZI is the new option for psoriatic arthritis.
Business
AbbVie, Capsida Set Sights on Gene Therapies for Eye Diseases
With more than $600 million on the line, AbbVie is expanding its strategic collaboration with Capsida Biotherapeutics to advance three gene therapy programs for eye diseases.
February 23, 2023
 · 
2 min read
 · 
Tristan Manalac
Courtesy of Abbvie Inc.
AbbVie Braces for Impact as Humira Biosimilars Hit the Market
AbbVie has officially reached the Humira cliff, and 2023 estimates are feeling the effects. The Illinois-based biopharma shared its Q4 and full-year 2022 results Thursday morning.
February 9, 2023
 · 
2 min read
 · 
Kate Goodwin
Courtesy of Abbvie Inc.
Business
AbbVie Braves Humira LOE, Remains Confident in Long-Term Growth
In a fireside chat at the 41st J.P. Morgan Healthcare Conference in San Francisco, CEO Rick Gonzalez said AbbVie is well-positioned for continued growth.
January 11, 2023
 · 
2 min read
 · 
Tristan Manalac
SKYRIZI is the new option for psoriatic arthritis.
Business
AbbVie, Anima Strike mRNA Deal Worth Up to $582M
Tuesday, AbbVie partnered with Anima Biotech to discover and develop mRNA modulators in a collaboration of up to $582 million. The partnership will focus on three oncology and immunology targets.
January 10, 2023
 · 
2 min read
 · 
Tristan Manalac
AbbVie_© AbbVie Inc. All rights reserved.
Business
AbCellera Continues Partnership Frenzy with AbbVie Antibody Discovery Pact
AbbVie and AbCellera inked an antibody discovery deal to develop candidates for up to five targets in several indications.
December 15, 2022
 · 
1 min read
 · 
Rosemary Scott
Load More
JOBS
View All Jobs at AbbVie
IN THE PRESS
Business
AbbVie Declares Quarterly Dividend - September 08, 2023
September 8, 2023
 · 
1 min read
BioMidwest
AbbVie to Present at the Morgan Stanley Healthcare Conference - September 6, 2023
September 6, 2023
 · 
1 min read
Job Trends
AbbVie Awards 45 Scholarships to U.S. Students Living With Chronic, Immune-Mediated Diseases
August 30, 2023
 · 
2 min read
Job Trends
AbbVie Submits Regulatory Applications to FDA and EMA for Risankizumab (SKYRIZI®) in Ulcerative Colitis
August 28, 2023
 · 
14 min read
Policy
AbbVie Announces European Commission Approval of AQUIPTA® (atogepant) for the Preventive Treatment of Migraine in Adults
August 17, 2023
 · 
11 min read
Business
AbbVie Reports Second-Quarter 2023 Financial Results
July 27, 2023
 · 
25 min read
Business
AbbVie and Calibr Expand Strategic Collaboration to Advance Several Preclinical and Early-stage Clinical Assets
July 26, 2023
 · 
4 min read
Drug Development
SKYRIZI® (risankizumab) Achieved Superiority Versus Apremilast for Co-Primary Endpoints Among Adult Patients with Moderate Plaque Psoriasis in Phase 4 Head-to-Head Study
July 26, 2023
 · 
12 min read
Drug Development
AbbVie Advances Immunology Pipeline with First Patient Dosed in Global Phase 3 Trial of Upadacitinib (RINVOQ®) in Hidradenitis Suppurativa
July 24, 2023
 · 
18 min read
BioMidwest
AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY®) for the Treatment of Adults with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
July 21, 2023
 · 
13 min read
Load More